Journal
ONCOTARGET
Volume 7, Issue 20, Pages 29824-29834Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.8035
Keywords
conditionally replicating adenoviruses; RNA interference; cancer; target therapy
Categories
Funding
- National Natural Science Foundation of China [3070099]
- Natural Science Foundation of Jiangsu Province [BK20151166]
Ask authors/readers for more resources
The small-interfering RNAs (siRNAs) have been employed to knockdown the expression of cancer-associated genes and shown some promise in cancer therapy. However, synthetic siRNA duplexes or plasmid mediated delivery of siRNAs have several problems, such as short half-life, low transfection efficiency and cytotoxicity associated with transfection. Conditionally replicating adenovirus (CRAds) as the delivery vector for short hairpin RNAs (shRNAs) could overcome these limitations and have shown augmented anti-tumor effects in experimental studies and preclinical trials. In this review, we summarize recent progress in the developmnt of CRAds-shRNA for cancer treatment. Combination of CRAds-shRNA with chemotherapeutics, radiation, dendritic cells, monoclonal antibodies and small-molecule inhibitors will be necessary to eradicate cancer cells and cancer stem cells and achieve superior outcomes. The use of CRAd platform for efficient delivery of shRNAs and foreign genes will open a new avenue for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available